Intraventricular urokinase for the treatment of posthemorrhagic hydrocephalus

Pediatric Neurology

Volumn 17, Issue 3, 1997, Pages 213-217

  Hansen, Anne R ^a   Volpe, Joseph J ^a   Goumnerova, Liliana C ^a   Madsen, Joseph R ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; FIBRINOLYTIC AGENT; PHENOBARBITAL; UROKINASE;

ARTICLE; BRAIN HEMORRHAGE; BRAIN VENTRICLE PERITONEUM SHUNT; CEREBROSPINAL FLUID DRAINAGE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HUMAN; HYDROCEPHALUS; INFANT; INFANT DISEASE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; PREMATURITY; PRIORITY JOURNAL; SEIZURE; TREATMENT OUTCOME;

AGE OF ONSET; CEREBRAL HEMORRHAGE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCEPHALUS; INFANT, NEWBORN; INJECTIONS, INTRAVENTRICULAR; MALE; PILOT PROJECTS; RISK FACTORS; THROMBOLYTIC THERAPY; URINARY PLASMINOGEN ACTIVATOR; VENTRICULOPERITONEAL SHUNT;

EID: 0030723150     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-8994(97)00130-6     Document Type: Article

References (16)

1. Volpe J. Neurology of the newborn, 2nd ed. Philadelphia: W.B. Saunders, 1995:403-63.
2. Dykes FD, Dunbar B, Lazarra A, Ahmann PA. Posthemorrhagic hydrocephalus in high-risk preterm infants: Natural history, management, and long-term outcome. J Pediatr 1989;14:611-8.
3. Whitelaw A, Rivers RPA, Creighton L, Gaffney P. Low dose intraventricular fibrinolytic treatment to prevent posthemorrhagic hydrocephalus. Arch Dis Child 1992;67:12-4.
4. Hill A, Shackelford GD, Volpe JJ. A potential mechanism of pathogenesis for early posthemorrhagic hydrocephalus in the premature newborn. Pediatrics 1984;73:19-21.
5. Whitelaw A. Endogenous fibrinolysis in neonatal cerebrospinal fluid. Eur J Pediatr 1993;132:928-30.
6. Whitelaw A, Saliba E, Fellman V, Mowinckel MC, Acolet D, Marlow N. Phase I study of intraventricular recombinant tissue plasminogen activator for treatment of posthaemorrhagic hydrocephalus. Arch Dis Child 1996;75:F20-6.
7. Ventriculomegaly Trial Group. Randomised trial of early tapping in neonatal posthaemorrhagic ventricular dilatation. Arch Dis Child 1990;65:3-10.
8. Hudgins RJ. Treatment of intraventricular hemorrhage in the premature infant with urokinase. Pediatr Neurosurg 1994;20:190-7.
9. Pinto M, Mitchell L, McCusker P, Andrew M. Standardization of prothrombin times in newborn infants. J Pediatr 1993;123:310-3.
10. Dufy MA, ed. Physician's desk reference 46th ed. Montvale, NJ: Medical Economics Data, 1992:503.
11. Shankaran S, Koepke T, Woldt E, Bedard MP, Dajani R, Eisenbrey AB, Canady A. Outcome after posthemorrhagic ventriculomegaly in comparison with mild hemorrhage without ventriculomegaly. J Pediatr 1989;114:109-14.
12. Whitelaw A, Mowinckel MC, Fellman V, Abildgaard U. Endogenous tissue plasminogen activator in neonatal cerebrospinal fluid. Eur J Pediatr 1996;155:117-9.
13. Whitelaw A, Mowinckel MC, Larsen ML, Rokas E, Abildgaard U. Intraventricular streptokinase increases cerebrospinal fluid D-dimer in preterm infants with posthaemorrhagic ventricular dilatation. Acta Paediatr 1994;83:270-2.
14. Rao JS, Chen M, Festoff BW. Plasminogen activator inhibitor 1, the primary regulator of fibrinolysis, in normal human cerebrospinal fluid. J Neurosci Res 1993;34:340-5.
15. Documenta Geigy. Scientific tables, 6th ed. Ardsley, NY: Geigy Pharmaceuticals, 1962:85.
16. Whitelaw A, Mowinckel MC, Abildgaard. Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: A limiting factor for clot lysis? Acta Paediatr 1995;84:933-6.